Qyuns Therapeutics Co., Ltd. Class H (HK:2509)
:2509
Want to see HK:2509 full AI Analyst Report?
2509 Stock Chart & Stats
HK$28.58
HK$0.02(0.29%)
At close: 4:00 PM EST
HK$28.58
HK$0.02(0.29%)
Day’s Range― - ―
52-Week RangeHK$10.76 - HK$36.50
Previous CloseN/A
Volume3.00K
Average Volume (3M)305.01K
Market Cap
HK$3.91B
Enterprise ValueHK$2.99B
Total Cash (Recent Filing)HK$558.90M
Total Debt (Recent Filing)HK$635.93M
Price to Earnings (P/E)12.3
Beta0.60
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding227,071,600
10 Day Avg. Volume194,489
30 Day Avg. Volume305,010
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)5.43
Price to Sales (P/S)4.80
P/FCF Ratio9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$33.50Price Target Upside17.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.72
Revenue Forecast (FY)HK$550.33M
Bulls Say, Bears Say
Bulls Say
Sharp 2025 Revenue And Margin InflectionA large revenue increase combined with high operating and net margins indicates the company achieved meaningful commercial or operational leverage in 2025. Sustained margins at this scale can fund R&D and commercialization, improve reinvestment capacity, and support durable profitability if execution continues.
Strong Cash Generation And ConversionRobust operating and free cash flow with near 1:1 conversion to net income demonstrates the business can convert earnings into real liquidity. Durable cash generation reduces reliance on external financing, supports debt paydown, and enables sustained investment in growth or defensive capital allocation over the medium term.
Improved Balance Sheet And High ROEMaterial equity growth and a markedly lower debt-to-equity ratio improve financial flexibility and reduce immediate refinancing pressure. The very high ROE indicates efficient use of capital in 2025, supporting the company's ability to generate shareholder value and fund strategic initiatives without excessive external funding.
Bears Say
Multi-year Volatility And Prior LossesA history of prolonged losses and swings in key financials implies execution and/or market risk that undermines confidence in a single-year recovery. Structural issues that produced instability previously could re-emerge, making the 2025 turnaround less reliable as a basis for long-term forecasts without multi-year confirmation.
Meaningful Absolute Debt LevelAlthough leverage ratios improved, a large absolute debt stock can constrain strategic flexibility and increase vulnerability to higher interest costs or cash-flow variability. For a biotech company, material debt raises refinancing and covenant risks and could limit the ability to fund R&D or scale without careful cash allocation.
Cash-flow Durability Not Yet ProvenThe pronounced swing to positive cash flow in one year follows multiple years of outflows, so repeatability is uncertain. If 2025 cash generation reflects one-off items or timing effects, future operating needs could again require external financing, undermining the long-term funding profile and raising execution risk.
Qyuns Therapeutics Co., Ltd. Class H News
2509 FAQ
What was Qyuns Therapeutics Co., Ltd. Class H’s price range in the past 12 months?
Qyuns Therapeutics Co., Ltd. Class H lowest stock price was HK$10.76 and its highest was HK$36.50 in the past 12 months.
What is Qyuns Therapeutics Co., Ltd. Class H’s market cap?
Qyuns Therapeutics Co., Ltd. Class H’s market cap is HK$3.91B.
When is Qyuns Therapeutics Co., Ltd. Class H’s upcoming earnings report date?
Qyuns Therapeutics Co., Ltd. Class H’s upcoming earnings report date is Aug 14, 2026 which is in 102 days.
How were Qyuns Therapeutics Co., Ltd. Class H’s earnings last quarter?
Qyuns Therapeutics Co., Ltd. Class H released its earnings results on Mar 27, 2026. The company reported HK$1.679 earnings per share for the quarter, beating the consensus estimate of N/A by HK$1.679.
Is Qyuns Therapeutics Co., Ltd. Class H overvalued?
According to Wall Street analysts Qyuns Therapeutics Co., Ltd. Class H’s price is currently Undervalued.
Does Qyuns Therapeutics Co., Ltd. Class H pay dividends?
Qyuns Therapeutics Co., Ltd. Class H does not currently pay dividends.
What is Qyuns Therapeutics Co., Ltd. Class H’s EPS estimate?
Qyuns Therapeutics Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qyuns Therapeutics Co., Ltd. Class H have?
Qyuns Therapeutics Co., Ltd. Class H has 227,071,600 shares outstanding.
What happened to Qyuns Therapeutics Co., Ltd. Class H’s price movement after its last earnings report?
Qyuns Therapeutics Co., Ltd. Class H reported an EPS of HK$1.679 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.485%.
Which hedge fund is a major shareholder of Qyuns Therapeutics Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2509
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Qyuns Therapeutics Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.56%
12-Months-Change
Fundamentals
Return on Equity
-48.44%
Trailing 12-Months
Asset Growth
70.24%
Trailing 12-Months
Company Description
Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. Class H (2509) is a biotechnology company focused on the development of innovative therapies for the treatment of various diseases, particularly in the fields of oncology and autoimmune disorders. The company specializes in research, development, and commercialization of biopharmaceutical products, leveraging cutting-edge technology and scientific research to address unmet medical needs. Qyuns Therapeutics aims to provide novel treatment options through its pipeline of drug candidates, enhancing patient care and outcomes.
2509 Stock 12 Month Forecast
Average Price Target
HK$33.50
▲(17.21% Upside)
Technical Analysis
Antengene Corporation Limited
―
Genor Biopharma Holdings Limited
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―
Options Prices
Currently, No data available
---